Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson's disease.Cell death and differentiation · 2021
   Pooled it
2. Endogenous ATP-powered nanomotors directing neural stem cell differentiation for Parkinson's disease treatment.Proceedings of the National Academy of Sciences of the United States of America · 2026
   Article
3. Repurposing the memory-promoting meclofenoxate hydrochloride as a treatment for Parkinson's disease through integrative multi-omics analysis.NPJ Parkinson's disease · 2025
   Article
4. Proteostasis disruption and lipid dyshomeostasis in neurodegeneration: exploring common druggable targets across sporadic and monogenic disorders.Frontiers in molecular neuroscience · 2025
   Review
5. Single-atom nanozyme liposome-integrated microneedles for in situ drug delivery and anti-inflammatory therapy in Parkinson's disease.Journal of nanobiotechnology · 2024
   Article
6. Reactive Oxygen Species-Associated Chiral Nanoarchitectures for Bioscience.Small science · 2024
   Article
7. Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson's disease.Nature communications · 2023
   Article
8. Detailed radiosynthesis of [Journal of labelled compounds & radiopharmaceuticals · 2023
   Article
9. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic α-synuclein oligomers in Parkinson's disease.Glycoconjugate journal · 2022
   Review
10. Brain regions susceptible to alpha-synuclein spreading.Molecular psychiatry · 2022
    Review
11. Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists.Journal of movement disorders · 2021
    Article
12. Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease.Frontiers in medicine · 2021
    Review
13. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System.Current neuropharmacology · 2021
    Article
14. Venoms as an adjunctive therapy for Parkinson's disease: where are we now and where are we going?Future science OA · 2020
    Review
15. Microglia-targeting nanotherapeutics for neurodegenerative diseases.APL bioengineering · 2020
    Article
16. Brain Hepcidin Suppresses Major Pathologies in Experimental Parkinsonism.iScience · 2020
    Article
17. Targeting the cholinergic system in Parkinson's disease.Acta pharmacologica Sinica · 2020
    Review
18. Frontiers in cell and developmental biology · 2020
    Review
19. Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy.BMB reports · 2020
    Review

Corrections and comments

• Erratum for
  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.2018

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract